Chinese clinical-stage biopharmaceutical firm Reistone Biopharma has secured nearly $100 million in a Series A round of financing to speed up the development of novel medicines for the treatment of immune and inflammation-related diseases.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
